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Infection after fracture osteosynthesis –
Part II: Treatment
Christian Fang1, Tak-Man Wong1,3, Kelvin KW To2,
Samson SY Wong2, Tak-Wing Lau1, and Frankie Leung1,3
Abstract
In the first part of this article, we have discussed the pathogenesis, clinical presentation, diagnosis and classification of
infection after fracture osteosynthesis with implants, termed here as osteosynthesis-associated infection (OAI). Pro-
longed antibiotic treatment is usually necessary. Implant retention and maintenance of fracture stability to allow for
fracture healing in spite of infection are allowed for OAI. Depending on the severity of infection, status of fracture healing
and host status, the treatment follows five common pathways. These are non-operative treatment, debridement with
implant retention, conversion of fixation, implant removal and suppression therapy. The decision-making process leading
to each treatment pathway and challenging scenarios is discussed in detail.
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Introduction
The term osteosynthesis-associated infection (OAI) is
defined as infection occurring after surgical fixation of
fractures with internally placed implants. The goal of treat-
ment is to eradicate infection, allow fracture healing, pre-
serve body function and prevent its recurrence.1
Presentation is heterogeneous and treatment is highly indi-
vidualized. Because of a lack of properly conducted com-
parative studies, the current discussion is at best based on
larger series by Torbert et al.,2 Berkes et al.3 and Rightmire
et al.,4 a number of smaller case series and heterogeneous
studies.
The three most important factors in devising a treatment
strategy for OAI are mechanical stability, time interval
between fixation and infection and the presence of union.
The other guiding factors are implant type, presence of
collections, non-viable bone, graft or substitute, soft tissue
and bone defect, joint involvement, host status and
response to treatment. Patients requiring surgical treatment
are best referred to subspecialized centres that are better
equipped.5 Patients should expect prolonged hospital stay,
multiple surgeries and prolonged use of intravenous anti-
biotics. Optimization of the general nutritional status and
co-morbid factors including smoking cessation is an impor-
tant part of general management.6
Fracture stability and implant retention
Although commonly considered as orthopaedic implant
infection, OAI is fundamentally different from prosthetic
joint infection (PJI). In PJI, permanent eradication is nec-
essary but difficult because of a large potential joint space
and sizable implants. Late haematogenous infection long
after surgery is common in PJI while early infection is more
common in OAI.
In OAI, implants can be definitively removed after frac-
ture union. The potential dead space is smaller. Involved
joints in OAI are lined by vulnerable living cartilage while
cartilage preservation is irrelevant for PJI. For late PJI, the
success rate of implant retention is as low as 15–54%,7
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while for OAI, when fracture stability is maintained, the
rate of successful hardware retention is 56–86%.3,4
The majority of OAI occurs within 10 weeks from sur-
gery.2 Even in the presence of infection, fractures can still
heal provided that it is vascular and stable.8 The ability to
heal is poor if there is sequestrum, bone defect and implant
loosening. Stability is important as movement across the
fracture causes soft tissue irritation, damage to revascular-
ization, haematoma and dead space formation. These fac-
tors are detrimental to both fracture healing and control of
infection.9
An infected and united fracture is easier managed than
an infected and non-united fracture.10 Even though the era-
dication of biofilm organisms maybe difficult with the
presence of implants, suppression of infection is possible
as long as collections, tissue necrosis and dead spaces are
minimal. If the hardware can provide much stability to the
fracture, it is preferentially retained until fracture union.
Treatment strategy
Acute infection 2 weeks after surgery
Around one-quarter of all OAIs presents within 2 weeks. They
are sometimes regarded as ‘superficial infections’ when
there is only mild wound edge erythema, superficial dis-
charge and breakdown. Ultrasonography or computed
tomography (CT) scans are helpful in detecting deep-
seated collections which are often not confirmable clini-
cally. Any deep-seated collections should be drained and
sent for microbiological tests. If it is certain that the infec-
tion is recent and superficial, empirical intravenous anti-
biotics for 2 weeks without surgical debridement may
suffice. In situations with large deep-seated collections,
persistent discharge or breakdown of wound edges, a for-
mal debridement with implant retention is indicated. Pre-
emptive drainage of wound haematomas that are doubtful
of being infected is indicated, especially in high-risk
regions like the tibia.
Delayed infection before expected fracture union
In delayed OAI occurring from 3 to 10 weeks after osteo-
synthesis, fracture healing is often incomplete. Biofilm for-
mation and osteomyelitis are moderate. The surgical
strategy is similar to the debridement, antibiotics and
implant retention protocol in PJI.11 Routine removal of
implants is best avoided as this may result in gross instabil-
ity and worsening of infection. Smoking, diabetes, medical
comorbidities, pseudomonas infection and open fractures
are risk factors for failed implant retention. External fixa-
tion with implant removal is necessary when the duration of
infection is prolonged or when implants are loose.4
From the two larger retrospective series by Berkes et al.3
and Rightmire et al.,4 the expected rate of successful hard-
ware retention with debridement and systemic antibiotics is
68–71%. Despite fracture healing being usually successful,
around 50% of implants would require eventual removal
for unresolved infections. OAIs with intramedullary (IM)
nails are thought to be associated with delayed diagnosis
and are more difficult to access surgically. Despite this,
Chen et al.12 reported high rates of successful retention of
IM nailing in patients with OAI after femur fractures. On
the other hand, patients who underwent removal and exter-
nal fixation experienced a higher incidence of non-union
and other complications.
Late infection with non-union
When infection presents at more than 10 weeks after osteo-
synthesis, it is nearly always well established and deep
seated. These are often regarded as infected non-unions.
Delayed diagnosis, implant loosening, tissue necrosis,
mature biofilm and sequestrum formation are usual. Exter-
nal bracing alone is unstable and non-surgical treatment is
likely to fail. Loose implants are no longer functional and
therefore must be removed or revised. The sequestrum
should be excised. Infection must be controlled before
reconstruction of bone defects. There is a low threshold for
conversion to external fixation.12,13 In situations where this
is not possible, revision of the internal fixation with stable
bridging implants is indicated. In a systematic review of 34
case series, a fracture union rate of 66–100%14 is generally
achievable by single- or two-stage surgery. However, up to
60% of patients may have persistence of infection after
fracture union.
Indolent infections must be suspected for all aseptic
non-unions, delayed unions and implant loosening. Speci-
men should be routinely sent for microbiology and histo-
logical examination. Around 20% of these cultures
specimen may return as ‘surprise’ positives. Still, the
chance of successful union is 80% when these situations
are adequately managed with antibiotics.15
Infection after fracture union
Management of infection after fracture union is usually
straightforward by debridement and implant removal. In
patients with previous OAI, implants should be preemp-
tively removed because infections are likely to recur from
biofilms.3,16 CT scans are useful in clarifying the status of
union when radiographs are doubtful. Patients associated
with osteomyelitis, septic arthritis or soft tissue defects are
managed accordingly following standard principles
(Figure 1).
General surgical considerations
Surgical debridement
Debridement of necrotic soft tissue, debris, pus and haema-
toma should proceed aggressively, while skin at the wound
margins is sparingly removed. The implant and fracture are
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assessed for stability. Exchange of implants reduces the
biofilm burden and allows for access to locations covered
by the plate. Devitalized bone should be removed in severe
and persistent infections even when structurally relevant.
Wound lavage is performed using a large amount of normal
saline. The use of antiseptics and high-flow pulsatile
systems17 is weakly supported by evidence but often
performed. Sizable bone voids can be filled with
antibiotic-impregnated spacers, and soft tissue defects are
controlled by meticulous closure, vacuum assistance or
flaps. Primary wound closure is preferred especially when
there is exposed bone.
A majority of patients will require more than two or
three debridements.4,16 A second look debridement should
be routinely planned and explained to patients before per-
forming the first. When there is doubtful tissue viability
and extensive tissue necrosis, re-exploration and debride-
ment should be performed every 2–3 days until a grossly
non-infected base with healthy bleeding bone and soft tis-
sue is obtained.
Use of external fixators
Complete implant removal and conversion to external fixa-
tor is indicated when there is failure of control after
repeated debridement or when there are multiple adverse
local and systemic factors.12 Illizarov-type ring external
fixators provide better fixation in cancellous bone. They
are particularly useful in the periarticular region where
preservation of joint motion is a concern. The success rate
of ring external fixation is high.18–20 The main drawbacks
include bulkiness, patient discomfort and very high rate of
pin tract infections. In patients with low systemic risks and
favourable soft tissue, conversion back to internal fixation
can be considered after the infection is controlled.21
Local antimicrobial therapy
Local antibiotic therapy is not strongly evidence-based but
commonly practiced.22 Knowledge is borrowed from PJI
where local antibiotic concentrations are increased with
Clinical features and initial treatment Investigations and Surgery
Early infection, minimal deep collection
No Surgery, close observation of 
progress 1st generation cephalosporin 
equvalent At least 2 weeks Fracture union 
Empirical antibiotics: 1st Generation 
cefazolin equvalent
Imaging, local examination, wound 
swab, aspiration
Empirical IV antibiotics Pathogen specific antibiotics
Consider early 
removal of implants
Failure to control Second stage 
surgery
Deep collection, abscess or sinus present, 
fracture not healed, no implant loosening
Debridement(s), retain internal 
fixation, obliterate dead space, soft 
tissue coverage Vancomycin equvalent
At least 6 weeks (First 2 weeks 
IV)
Spacer removal 
and bone 
grafting Fracture union 
Preoperative: Withhold empirical 
antibiotics unless sepsis
Imaging, local examination, wound 
swab, aspiration
Empirical IV antibiotics /  Unless 
known pathogen
Pathogen specific antibiotics
Consider early 
removal of implants
Failure to control Second stage 
surgery
Sub-acute / Late infection, deep collection 
or sinus present, fracture not healed, 
implant loosening, failure of control
Debridement(s), removal of implants, 
external fixator, obliterate dead 
space, soft tissue coverage Vancomycin equvalent
At least 6 weeks (First 2 weeks 
IV)
Spacer removal 
and bone 
grafting Fracture union 
Preoperative: Withhold empirical 
antibiotics unless sepsis
Imaging, local examination, wound 
swab, aspiration
Empirical IV antibiotics /  Unless 
known pathogen
Pathogen specific antibiotics
Consider internal 
refixation if infection 
controlled
Infection after union, mechanically stable
Debridement(s), irrigation, removal of 
implants, obliterate dead space, soft 
tissue coverage
1st generation cephalosporin 
equvalent At least 2 weeks
Preoperative: Withhold empirical 
antibiotics unless sepsis
Imaging, local examination, wound 
swab, aspiration
Empirical IV antibiotics /  Unless 
known pathogen
Pathogen specific antibiotics
Any of above, medically unfit or unwilling 
for surgery
No Surgery, close observation of 
progress 1st generation cephalosporin 
equvalent Lifelong Fracture union 
Preperative: Withhold empirical antibiotics 
unless sepsis
Imaging, local examination, wound 
swab, aspiration
Empirical IV antibiotics Pathogen specific antibiotics
Reconsider surgical 
removal
4. Implant removal
5. Suppression 
eracretfAyparehtcitoibitnA
1. Non-operative
2. Implant retention
3. Conversion of 
fixation
Significant bone defect: Antibiotic PMMA cement spacer 
Significant bone defect: Antibiotic PMMA cement spacer 
Figure 1. Outline of five different treatment pathways for OAI in different clinical situations. The management pathway should be
stepped up upon failure of control from (1) non-operative treatment to (2) implant retention and lastly to (3) conversion of fixation. (4)
Implant removal is performed after fracture union and (5) suppression therapy is recommended for poor surgical candidates. OAI:
osteosynthesis-associated infection.
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minimal systemic toxicity.23 The various options include
commercially available antibiotic impregnated polymethyl
methacrylate (PMMA) beads,24,25 antibiotic-loaded
PMMA bone cement spacers26,27 and antibiotic-loaded
PMMA-coated IM rods.28 Even local application of vanco-
mycin to the operative site has appeared to reduce infection
in high-risk surgeries.29
Antibiotic beads are used in contaminated open wounds
with smaller sized bone and soft tissue voids.30 They are
commercially prepared and relatively easy to remove. It is
indicated when stability of the fracture is maintained and
short-term filling is desired.
A two-stage approach with antibiotic-laden spacer and
subsequent reconstruction appears to be relatively simple,
effective and predictable compared to other elaborate
means.31 Masquelet and Begue27 described the technique
of antibiotic cement spacer-induced membrane and delayed
bone grafting. This technique has high success and low
complication rates for traumatic and infection-related bone
defects.26,31,32 At debridement, sizable defects are tempo-
rarily filled with antibiotic-laden cement which also pro-
vides structural support and prevents fibrous ingrowth.
Since PMMA curing is exothermic, heat injury and dena-
turing of impregnated drugs are possible. Heat stable water-
soluble drugs such as aminoglycosides, vancomycin and
imipenem are preferred. Combining two or more antibio-
tics in a single spacer is common and shown to be syner-
gistic in vivo.33 The amount of antibiotics used is typically
up to 10% by weight for PJI. For example, 0.5–1 g of
gentamicin and 2–4 g of vancomycin is mixed with 40 g
of PMMA cement in our usual practice. Higher concentra-
tions of antibiotics may be considered, as structural integ-
rity is less relevant to OAI. The mixing of PMMA is
performed without vacuum, so that porosities, irregularities
and the surface area for drug release are increased.34
The rate of antibiotic elusion varies between drugs and
geometries of the spacer.35 It should be noted that a high
concentration is released within a very short period hours
after implantation, and the local concentration is exponen-
tially reduced within a few days.36 Since an inhibitory con-
centration is not reliably maintained after 2 weeks, it is
mandatory to supplement local antibiotics with systemic
therapy.37 Retained PMMA spacers can become a nidus
for infection and should therefore be routinely removed.
Second-stage cancellous bone grafting is performed
after 6–8 weeks. A pseudo-membrane can usually be found
enclosing the PMMA spacer. Although the cellular and
molecular mechanism behind this induced membrane is
still being studied, it is usually vascular and rich in growth
factors.26 Tissue samples are obtained to document clear-
ance of infection, and graft material is placed within this
viable clean cavity.38,39 Placement of bone graft and bone
substitutes in the presence of uncontrolled infection is con-
traindicated (Figures 2 and 3).
Specific challenging scenarios
Massive bone defects
Bone defects are common in OAI, and sometimes a neces-
sary evil resulting from adequate debridement of the seques-
trum. When such defects are segmental, fracture healing is
compromised. A plethora of techniques exists in the man-
agement of bone defects.40 It is repeatedly mentioned that
priority must be given for eradiation of infection before
tackling of bone defects.41 The majority of smaller defects
of less than 4 cm is usually handled successfully with the
two-stage antibiotic PMMA spacer-induced membrane tech-
nique mentioned above. A study reported reduced reinfec-
tion rates when bone graft is mixed with local antibiotics.42
Figure 2. The PMMA-induced spacer technique at the bone grafting stage in a patient with distal tibia bone defect. After control of the
infection, the fibrous pseudo-capsule encasing the PMMA spacer is opened and autogenous bone graft is placed within a well-contained
cavity. PMMA: polymethyl methacrylate.
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A combination of techniques can be used to archive
success in massive defects.43 Distraction osteogenesis with
circular fixators is useful for larger segmental defects espe-
cially when realignment of deformities is also desired.44
The risks are refractures, pin tract infections, soft tissue
impingement and neurovascular complications.45 Internal
fixation augmentation after docking shortens the time
needed for external fixation without considerable risk of
reinfection.46,47 The Papineau technique employs open
cancellous bone grafting for problematic osseous defects
with overlying soft tissue defect with high rate of reported
success48; however, the need for repetitive dressing is
intensive from the nursing perspective and wound healing
by secondary intension and relatively slow.
Tibialization of the fibula or graft-induced tibiofibular
synostosis is an option for isolated tibial defects with an
intact fibula.49 Free vascularized bone transfers are techni-
cally demanding but useful for massive defects at a slight
danger of flap loss, stress fractures and the need for
extended periods of protection.
Soft tissue defects
Routine wound closure and avoidance of exposed bone and
hardware are recommended. Suction drainage should be
placed into deep cavities and potential dead spaces to pre-
vent retention of haematoma. Locations with thin soft tis-
sue envelope such as the clavicle, patella and distal tibia are
especially difficult, and primary closure can be challenging
even when the defect is as small as 2 cm.
Flaps are needed for severe soft tissue defects. Free
tissue transfer in young patients has high reported success
rate even when implants are transiently exposed.50–52 Risk
factors for failure of free tissue transfer are tobacco smok-
ing, renal or liver failure, immune deficiency, chronic
hypoxia, malignancy, diabetes, old age, steroid use, alco-
holism and substance abuse.53
Acute shortening is relatively easy and safe,54,55 effec-
tively reliving soft tissue tension and reducing dead space.
It is particularly useful when there is combined soft tissue
and bone defect, optionally followed by distraction
osteogenesis.
Negative pressure wound therapy (NPWT) may be used
to assist wound coverage accelerate granulation formation
and removal of exudate in OAI. It is a useful bridging
therapy while waiting for granulation base to develop for
skin grafting or to accelerate healing by secondary inten-
sion in smaller defects. Importantly, early closure of open
fractures by 5–7 days remains the best way to reduce the
risk of nosocomial infection, and prolonged NPWT should
not be used as a substitute for early wound closure and flap
coverage.56
Infection after IM nailing
OAIs after IM nailing are uniquely challenging to manage.
The IM canal is surgically less accessible, and diagnosis is
more likely to be delayed. Treatment is based upon the
same principles of stabilization, systemic antibiotics, sur-
gical debridement, soft tissue coverage and staged bone
defect management.57 Makridis et al.58 devised a surgical
management protocol based on three different stages of
infection. For early infections, implant retention with or
without debridement is sufficient. For delayed infections,
debridement, reaming and nail exchange with usual or anti-
biotic laden implants are suggested. For late infections,
debridement, nail exchange or conversion to external fixa-
tion is recommended.
Antibiotic cement-coated rods are increasingly being
used for IM infections. A number of small series reported
success using them as temporary means for fracture stabi-
lization and local bacterial killing,59–62 followed by refixa-
tion with a new IM nail around 2 months later. A large bore
chest tube can be used as an economical mould in which
Figure 3. Serial radiograph of the same patient from before cement removal and bone grafting (0 m) showing union and remodelling up
to 20 months.
Fang et al. 5
PMMA is injected and cured around a rush pin or an
Ender’s nail.63 When axial and rotational stability is
required, PMMA-coated small diameter interlocking nails
can be used63 or antibiotic beads can be placed within
slotted nails to attain a similar effect.
Reaming effectively removes infected IM debris and
bone. The reamer irrigator aspirator (RIA) is a specialized
single use reamer which allows simultaneous irrigation and
suction within the IM cavity. A number of small studies64–66
have reported a success rate of 96–100% using RIA and
antibiotic cement rods to treat IM osteomyelitis. RIA
appears safe, although more studies are needed to confirm
its theoretical advantages in infection, prevention of fat
embolism and prevention of thermal necrosis.
Articular involvement
Synovial joints are poorly perfused inherent dead spaces
with vulnerable cartilage. Articular involvement is notor-
iously difficult to manage in OAI. Involvement of the knee
and ankle is associated with high-energy tibial plateau and
pilon fractures. Shoulder and elbow OAI may lead to very
poor results.
Based on experience, we routinely immobilize infected
joints after debridement. This is notably dissimilar to PJIs
where cartilage preservation is irrelevant, and mobilization
is usually allowed with articulated antibiotic-loaded
spacers. With immobilization, stiffness is common but con-
trol of infection is usually more predictable. An uncon-
trolled infection in a synovial joint is worse than a stiff
joint with relatively preserved cartilage. After control of
the infection, it is possible to regain significant functional
ranges by open or arthroscopic releases in the shoulder,
elbow and knee.
Arthrodesis is considered when salvage of a destroyed
joint is impossible.67 Prosthetic replacement should be car-
ried out in two stages with antibiotic-impregnated spacers
after complete clearance of infection in order to minimize
the risk of contamination.68 Tumour prosthesis replace-
ment of large defects carries around one-quarter risk of
reinfection.69
Amputation is indicated when there are significant sys-
temic adverse factors. Those with considerable soft tissue
defects are less suitable for joint prosthesis and more suited
for amputation or fusion.70 In special circumstances, ampu-
tations may be performed distal to the infection to reduce
mechanical and vascular load.71
Systemic treatment
Pharmacological treatment of OAI is mandatory. This can
be divided into three stages: empirical treatment, specific
targeted treatment and occasional need for long-term sup-
pression. In the selection of antibiotics, bacterial suscept-
ibility, bone penetration and side effects should be
considered.
Empirical antibiotics
Empirical intravenous antibiotics can successfully treat
early and superficial infections that do not have well-
established biofilms. Antibiotics do not penetrate into hae-
matoma, seroma, abscess or devitalized bone and necrotic
soft tissue. High-dose intravenous administration can best
ensure bactericidal concentrations in poorly perfused bone
and peri-implant areas.
Staphylococcus aureus, in particular, methicillin-
sensitive S. aureus, remains a common cause of OAI in the
community; anti-staphylococcal antibiotics such as
penicillinase-resistant penicillin (e.g. cloxacillin) or first-
generation cephalosporin (e.g. cefazolin) are first-line drugs
for empirical coverage. In patients with previous history of
methicillin-resistant S. aureus infections, and those with pro-
longed hospitalization or institutional care, glycopeptide
such as vancomycin or teicoplanin should be used for
empirical treatment. Third-generation cephalosporin such
as cefotaxime or ceftriaxone should be considered for OAI
around the perineum,2 elderlies, diabetics or immunocom-
promised patients because they are at higher risk of gram-
negative infections.
In delayed and late infections occurring more than 3
weeks after osteosynthesis, less virulent organisms such
as coagulase negative staphylococci (CNS) or unusual
organisms are common. Empirical treatment must not
interfere with a rapid microbiological diagnosis. Unless
in severe sepsis, empirical therapy is withheld until deep
tissue and fluid samples are obtained. It is important to note
that 80–90% of CNS are resistant to methicillin. Prolonged
treatment with a targeted drug is needed in delayed cases
because bone and implant involvement is usually estab-
lished. Misidentification of delayed or late OAIs and inade-
quacy in antibiotic treatment commonly leads to persistent
bacterial residence and development of resistance.
Targeted antibiotics
Resistant strains can account for more than 50% of S. aur-
eus and 32% of all organisms that cause OAI.2 Target-
specific therapy should begin as soon as culture isolates
and antibiotic susceptibility patterns become available.
When a specific microorganism is identified, the broad-
spectrum empirical drug is changed to a narrow-spectrum
target-specific antibiotic to minimize host flora suppression
and emergence of resistance. Polymicrobial growth is asso-
ciated with contaminated open fractures and poor host
immunity. A combination of drugs is usually necessary.
For staphylococci infections, combined therapies with
rifampicin have shown increased in vitro and in vivo
eradication compared to monotherapy with quinolone or
b-lactams and superior biofilm penetration. A few prospec-
tive studies demonstrated the cure rates of 69–100% using a
6-month rifampicin–quinolone combination regimen, espe-
cially in earlier infections.72,73
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Duration of antibiotics
In all situations, we recommend initial high-dose intrave-
nous treatment for 3 weeks. Prolonged therapy is always
necessary in delayed or late infections with implants. In
patients showing rapid response, this may be changed to
oral drugs with high bioavailability in bone.74 A peripher-
ally inserted central catheter simplifies long-term venous
access with minimal risks. It is necessary to regularly mon-
itor inflammatory parameters, local conditions and radiolo-
gical evidence of fracture healing and implant loosening.
Antibiotics are stopped only when there is clinical resolu-
tion of infection, normalization of biochemical markers and
radiological signs of good fracture stability, no implant
loosening and progressive healing. When in doubt, positron
emission tomography – computed tomography (PET-CT)
scans are useful in monitoring both the status of infection
and fracture healing.
The minimal duration of antimicrobial therapy for
delayed OAI is 6 weeks with retained implants when
patients have optimal response both clinically and bio-
chemically. This is increased to 3 months or more if initial
control is not rapid and adverse factors local or systemic are
present. The duration can be reduced to 3 weeks if all
implants are removed with good local control and fracture
healing (Table 1).
Failed eradication and long-term suppression
Failure of control and re-emergence of infection usually
happens within 3 months after stopping antibiotics.75
Long-term suppression therapy is indicated when fracture
healing is incomplete or when surgical treatment is impos-
sible. Suppression should not be a routine alternative to
surgery because of increased risk of adverse drug reactions
and bacterial resistance. Fracture healing can occur during
drug suppression, and implant removal is still strongly
advised afterwards.
Adverse effects
Adverse drug reactions often occur when antibiotic treat-
ment is prolonged. These include allergy, drug rash,
antibiotic-associated colitis, bone marrow suppression,
leukopenia, thrombocytopenia and drug fever. Specific
side effects for rifampicin include liver impairment and
thrombocytopenia. For vancomycin, patients may develop
renal impairment. Patients on daptomycin can develop
myositis with need to monitor creatine kinase.76 Monitory
measures for side effects are necessary at constant time
intervals. Patients suspected to be suffering from adverse
reactions should receive advice from infectious disease
specialists.
Table 1. Recommended antibiotics (choice of antibiotics should be guided by antibiotic susceptibility testing results)a.
Initial treatment Oral maintenance
Methicillin-susceptible Staphylococcus species Cloxacillin or flucloxacillin þ rifampicin or
Cephazolin þ rifampicin
Quinolone þ rifampicin or
Co-trimoxazoleb or
Fusidic acidb or
Minocycline or
Clindamycin or
Linezolid
Methicillin-resistant Staphylococcus species Vancomycin or
Daptomycin
Quinolone þ rifampicin or
Co-trimoxazoleb or
Fusidic acidb or
Minocycline or
Clindamycin or
Linezolid
Streptococcus Penicillin G or
Ceftriaxone
Vancomycin
Amoxicillin or
Clindamycin or
Linezolid
Enterococcus – penicillin susceptible Ampicillin
Enterococcus – penicillin resistant Vancomycin or
Daptomycin or
Linezolid
Enterobacteriaceae b-Lactam Ciprofloxacin
Pseudomonas aeruginosa Ceftazidime or
Meropenem
Ciprofloxacin
Propionibacterium Penicillin G or
Clindamycin
Amoxicillin or
Clindamycin
aModified from Mandell, Douglas, and Bennett’s principles and practices of infectious diseases (Eighth edition). Gerald L. Mandell, John E. Bennett,
Raphael Dolin. Chapter 107. Authors: Werner Zimmerli, Parham Sendi.
bShould be used in combination with other oral antibiotics, except rifampicin.
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Drug fever presents a specific diagnostic dilemma.
Unlike uncontrolled infection, there is improved local
symptoms and signs, improving erythrocyte sedimentation
rate (ESR), C-Reactive Protein (CRP) and low leukocyte
counts. Antibiotics are stopped or switched to a different
class and patients are observed closely without additional
surgery. Alternatively, if local and systemic features
remain doubtful, strong consideration is given to perform
additional debridement together with modification of
antibiotics.
Ongoing developments
Dipstick leukocyte esterase colorimetric measurement is
recently being evaluated as a cost-effective and rapid test
using synovial aspirates in PJI with high sensitivity and
specificity.77 The role of this test has not yet been investi-
gated in OAI. Novel molecular markers based on immuno-
globulin G (IgG) antibodies are being studied as an
alternative technique for pathogen identification.78 In addi-
tion to sonification, electrical stimulation and laser-
generated shockwaves may enhance detachment of bio-
films organisms from implants for diagnosis.79,80
Implant designs are being altered for the prevention and
control of OAI in a number of ways.81 Specialized coating
materials82 and drug eluting implants are currently being
developed.83,84 Nanostructured surface finishing85 and
hydrophilic surface materials such as polyethylene oxide,86
bioactive copper and silver may inhibit bacterial adhesion
and biofilm formation. Prophylactic use of antibiotic-
coated nails is being investigated for open fractures.87
A pilot study showed that local application of bismuth
thiols may be effective in preventing infections in open
fractures.88 Local antibiotic delivery and dead space con-
trol maybe enhanced using specialized water-soluble gels
or polymers other than PMMA which are also less exother-
mic.89,90 The role of biological agents such as bone mor-
phological proteins that speed up bone healing is being
investigated in OAI.91,92 The cationic steroid antibiotic
CSA-90 is a novel drug being investigated for both bone
stimulation and bactericidal properties.93
Summary
Overall, the subject of OAI remains to be challenging and is
predominantly an experience-based practice. Once more,
we emphasize the importance of maintaining mechanical
stability in any treatment strategy. Two-stage use of
antibiotic-loaded PMMA spacers appears to result in more
predictable success than single-stage strategies. Much
knowledge gaps remain to be filled by properly conducted
clinical research. Investigations in novel techniques and
robust comparative studies are particularly needed. While
randomized studies are hard to conduct in this heteroge-
neous group of patients, establishment of large
international multicentre bone infection registries may pro-
vide useful insights.
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